FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1897882788> ?p ?o ?g. }

• W1897882788 endingPage "85" @default.
• W1897882788 startingPage "78" @default.
• W1897882788 abstract "PurposeTo assess the safety and tolerability of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, when administered in combination with an anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg, by intravitreal injection in participants with neovascular age-related macular degeneration (NVAMD).DesignProspective phase 1 clinical trial.ParticipantsA total of 23 participants diagnosed with NVAMD and aged 50 years or older were enrolled.MethodsPart 1 included 15 participants. Three participants received a single intravitreal E10030 (0.03 mg) injection and were subsequently given intravitreal ranibizumab (0.5 mg) injections at weeks 2, 6, and 10. Twelve participants (3 per group) received E10030 (0.03, 0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) at day 0, month 1, and month 2 in an ascending manner. In Part 2 (8 participants), E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) was injected at day 0, month 1, and month 2.Main Outcome MeasuresSafety at week 12 was the primary outcome and included assessment of vital signs, laboratory tests, and serial eye examinations. Other safety metrics included assessment through week 24 of Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) and biomarker changes evaluated by optical coherence tomography (OCT) and fluorescein angiography (FA).ResultsAll doses of intravitreal E10030 administered in combination with ranibizumab were well tolerated. No dose-limiting toxicities or relevant safety events were noted at any dose level during the study. Investigators did not report adverse events related to E10030 or ranibizumab. Mean VA change was a gain of 14 letters, and 59% of participants gained ≥15 letters from baseline at week 12. On FA at week 12, there was an 85.5% mean reduction from baseline in choroidal neovascularization (CNV) size. On OCT at the week 12 visit, there was a mean decrease in center point thickness and central subfield thickness of 38.9% and 33.7%, respectively.ConclusionsIntravitreal E10030 administered at doses up to 3 mg in combination with ranibizumab was well tolerated without evidence of systemic or ocular toxicity in participants with NVAMD. The changes in both mean VA and imaging biomarkers suggest a favorable short-term safety profile for the combination therapy of E10030 and ranibizumab. To assess the safety and tolerability of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, when administered in combination with an anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg, by intravitreal injection in participants with neovascular age-related macular degeneration (NVAMD). Prospective phase 1 clinical trial. A total of 23 participants diagnosed with NVAMD and aged 50 years or older were enrolled. Part 1 included 15 participants. Three participants received a single intravitreal E10030 (0.03 mg) injection and were subsequently given intravitreal ranibizumab (0.5 mg) injections at weeks 2, 6, and 10. Twelve participants (3 per group) received E10030 (0.03, 0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) at day 0, month 1, and month 2 in an ascending manner. In Part 2 (8 participants), E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) was injected at day 0, month 1, and month 2. Safety at week 12 was the primary outcome and included assessment of vital signs, laboratory tests, and serial eye examinations. Other safety metrics included assessment through week 24 of Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) and biomarker changes evaluated by optical coherence tomography (OCT) and fluorescein angiography (FA). All doses of intravitreal E10030 administered in combination with ranibizumab were well tolerated. No dose-limiting toxicities or relevant safety events were noted at any dose level during the study. Investigators did not report adverse events related to E10030 or ranibizumab. Mean VA change was a gain of 14 letters, and 59% of participants gained ≥15 letters from baseline at week 12. On FA at week 12, there was an 85.5% mean reduction from baseline in choroidal neovascularization (CNV) size. On OCT at the week 12 visit, there was a mean decrease in center point thickness and central subfield thickness of 38.9% and 33.7%, respectively. Intravitreal E10030 administered at doses up to 3 mg in combination with ranibizumab was well tolerated without evidence of systemic or ocular toxicity in participants with NVAMD. The changes in both mean VA and imaging biomarkers suggest a favorable short-term safety profile for the combination therapy of E10030 and ranibizumab." @default.
• W1897882788 created "2016-06-24" @default.
• W1897882788 creator A5007681234 @default.
• W1897882788 creator A5018888370 @default.
• W1897882788 creator A5038698286 @default.
• W1897882788 creator A5045104105 @default.
• W1897882788 creator A5083062590 @default.
• W1897882788 creator A5090864408 @default.
• W1897882788 date "2016-01-01" @default.
• W1897882788 modified "2023-09-26" @default.
• W1897882788 title "A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration" @default.
• W1897882788 cites W1500728559 @default.
• W1897882788 cites W1603230122 @default.
• W1897882788 cites W1968189763 @default.
• W1897882788 cites W1973418567 @default.
• W1897882788 cites W2003797682 @default.
• W1897882788 cites W2011187017 @default.
• W1897882788 cites W2014975030 @default.
• W1897882788 cites W2021017423 @default.
• W1897882788 cites W2023848963 @default.
• W1897882788 cites W2068742492 @default.
• W1897882788 cites W2071219047 @default.
• W1897882788 cites W2085712747 @default.
• W1897882788 cites W2104764481 @default.
• W1897882788 cites W2108445835 @default.
• W1897882788 cites W2112940666 @default.
• W1897882788 cites W2115390024 @default.
• W1897882788 cites W2116433781 @default.
• W1897882788 cites W2124264886 @default.
• W1897882788 cites W2131393213 @default.
• W1897882788 cites W2138831539 @default.
• W1897882788 cites W2155214429 @default.
• W1897882788 cites W2169199162 @default.
• W1897882788 cites W4245635197 @default.
• W1897882788 cites W4250031098 @default.
• W1897882788 cites W4253705647 @default.
• W1897882788 doi "https://doi.org/10.1016/j.ophtha.2015.09.004" @default.
• W1897882788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26499921" @default.
• W1897882788 hasPublicationYear "2016" @default.
• W1897882788 type Work @default.
• W1897882788 sameAs 1897882788 @default.
• W1897882788 citedByCount "76" @default.
• W1897882788 countsByYear W18978827882016 @default.
• W1897882788 countsByYear W18978827882017 @default.
• W1897882788 countsByYear W18978827882018 @default.
• W1897882788 countsByYear W18978827882019 @default.
• W1897882788 countsByYear W18978827882020 @default.
• W1897882788 countsByYear W18978827882021 @default.
• W1897882788 countsByYear W18978827882022 @default.
• W1897882788 countsByYear W18978827882023 @default.
• W1897882788 crossrefType "journal-article" @default.
• W1897882788 hasAuthorship W1897882788A5007681234 @default.
• W1897882788 hasAuthorship W1897882788A5018888370 @default.
• W1897882788 hasAuthorship W1897882788A5038698286 @default.
• W1897882788 hasAuthorship W1897882788A5045104105 @default.
• W1897882788 hasAuthorship W1897882788A5083062590 @default.
• W1897882788 hasAuthorship W1897882788A5090864408 @default.
• W1897882788 hasBestOaLocation W18978827881 @default.
• W1897882788 hasConcept C118487528 @default.
• W1897882788 hasConcept C126322002 @default.
• W1897882788 hasConcept C134018914 @default.
• W1897882788 hasConcept C141071460 @default.
• W1897882788 hasConcept C197934379 @default.
• W1897882788 hasConcept C2776403814 @default.
• W1897882788 hasConcept C2776694085 @default.
• W1897882788 hasConcept C2777802072 @default.
• W1897882788 hasConcept C2778257484 @default.
• W1897882788 hasConcept C2778375690 @default.
• W1897882788 hasConcept C2779829184 @default.
• W1897882788 hasConcept C2780248432 @default.
• W1897882788 hasConcept C2781100027 @default.
• W1897882788 hasConcept C2781359195 @default.
• W1897882788 hasConcept C555293320 @default.
• W1897882788 hasConcept C71924100 @default.
• W1897882788 hasConceptScore W1897882788C118487528 @default.
• W1897882788 hasConceptScore W1897882788C126322002 @default.
• W1897882788 hasConceptScore W1897882788C134018914 @default.
• W1897882788 hasConceptScore W1897882788C141071460 @default.
• W1897882788 hasConceptScore W1897882788C197934379 @default.
• W1897882788 hasConceptScore W1897882788C2776403814 @default.
• W1897882788 hasConceptScore W1897882788C2776694085 @default.
• W1897882788 hasConceptScore W1897882788C2777802072 @default.
• W1897882788 hasConceptScore W1897882788C2778257484 @default.
• W1897882788 hasConceptScore W1897882788C2778375690 @default.
• W1897882788 hasConceptScore W1897882788C2779829184 @default.
• W1897882788 hasConceptScore W1897882788C2780248432 @default.
• W1897882788 hasConceptScore W1897882788C2781100027 @default.
• W1897882788 hasConceptScore W1897882788C2781359195 @default.
• W1897882788 hasConceptScore W1897882788C555293320 @default.
• W1897882788 hasConceptScore W1897882788C71924100 @default.
• W1897882788 hasIssue "1" @default.
• W1897882788 hasLocation W18978827881 @default.
• W1897882788 hasLocation W18978827882 @default.
• W1897882788 hasOpenAccess W1897882788 @default.
• W1897882788 hasPrimaryLocation W18978827881 @default.
• W1897882788 hasRelatedWork W1995044506 @default.
• W1897882788 hasRelatedWork W2011764310 @default.
• W1897882788 hasRelatedWork W2042956061 @default.

• next